OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany; German Cancer Consortium DKTK, Dresden, Germany; Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.
OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.
Semin Cancer Biol. 2017 Jun;44:10-24. doi: 10.1016/j.semcancer.2017.02.011. Epub 2017 Feb 28.
Metastatic tumors are the cause of more than 90% of cancer related deaths. Metastasis formation can be considered as a culmination of the Darwinian evolutionary process within the tumor, when competition of multiple clones results in the development of cell inherent traits that favor tumor dissemination. Cancer stem cells (CSC) which possess self-renewal properties and genomic instability are considered to be an engine of tumor evolution. Cancer cells which have the capacity to colonize distant organs have the features of CSC and, in addition, exert their tumor-initiating capacity under adverse microenvironmental conditions. Recent studies support an idea that metastases can be driven by the evolved and selected subpopulations of CSC. In this review we discuss the common hallmarks of CSC and metastasis initiating cells (MIC) and prospects for the development of anti-metastatic therapy.
转移瘤是 90%以上癌症相关死亡的原因。转移的形成可以被认为是肿瘤内达尔文进化过程的顶点,当多个克隆的竞争导致有利于肿瘤扩散的细胞固有特性的发展时。具有自我更新特性和基因组不稳定性的癌症干细胞(CSC)被认为是肿瘤进化的引擎。具有定植远处器官能力的癌细胞具有 CSC 的特征,此外,在不利的微环境条件下发挥其肿瘤起始能力。最近的研究支持这样一种观点,即转移可以由 CSC 和转移起始细胞(MIC)的进化和选择亚群驱动。在这篇综述中,我们讨论了 CSC 和转移起始细胞(MIC)的共同特征以及抗转移治疗的发展前景。